ATSBlueEditor Profile Banner
ATS Blue Journal Profile
ATS Blue Journal

@ATSBlueEditor

Followers
20K
Following
443
Media
5K
Statuses
7K

Posting content from the American Journal of Respiratory and Critical Care Medicine; follows do not indicate endorsement. #pulmCC #sleepmed #AJRCCM #RespEd #ATS

Joined December 2014
Don't wanna be here? Send us removal request.
@ATSBlueEditor
ATS Blue Journal
18 days
📣Call for Papers!📣. Looking for articles highlighting adult and pediatric critical care . 📆Deadline: September 22, 2025 . 🔬Learn More Here: 🖱️Submit here: @atscommunity #medsky
Tweet media one
0
1
0
@ATSBlueEditor
ATS Blue Journal
2 days
Ansa Cervicalis Stimulation During Non–Rapid Eye Movement Sleep in a Patient with Obstructive Sleep Apnea.@atscommunity . 🔓 Open Access. 🔗
Tweet media one
0
0
1
@ATSBlueEditor
ATS Blue Journal
2 days
Right ventricular strain (RVGLS) & RVOT VTI are powerful predictors of mortality in ICU patients with pulmonary embolism.@atscommunity . Find the article here: Watch here:
0
1
3
@ATSBlueEditor
ATS Blue Journal
3 days
Tune into this podcast as experts break down the epidemiology & impact of cough in ILD care: Epidemiology and Prognostic Significance of Cough in Fibrotic Interstitial Lung Disease.@atscommunity .
0
1
2
@ATSBlueEditor
ATS Blue Journal
3 days
Using the 2024 National Academies of Science, Engineering, and Medicine Definition of Long COVID: Implications for Pulmonary and Critical Care Medicine. Experts in pulmonary and critical care medicine discuss the 2024 NASEM definition of Long COVID. 🔗
0
4
5
@ATSBlueEditor
ATS Blue Journal
4 days
The Blue Journal thanks Saskia Janssen, MD, PhD, for her contribution to the August issue. Telacebec, a Potent Agent in the Fight against Tuberculosis: Findings from a Randomized, Phase 2 Clinical Trial and Beyond .
Tweet media one
0
0
0
@ATSBlueEditor
ATS Blue Journal
4 days
Addressing Knowledge Gaps in the Early Detection of Bronchiolitis Obliterans Syndrome After Hematopoietic Cell Transplantation: An Official ATS Research Statement. This research roadmap targets key gaps to advance early detection and improve outcomes. 🔗
Tweet media one
0
3
8
@ATSBlueEditor
ATS Blue Journal
4 days
📣Call for Papers! 📣 . Looking for articles highlighting the spectrum of discovery in thoracic malignancies . 📅Deadline: October 28, 2025 . 🔬Learn More Here: . 🖱️Submit here: @atstoa @atscommunity
Tweet media one
0
0
1
@ATSBlueEditor
ATS Blue Journal
4 days
📣Call for Papers!📣 . Looking for articles highlighting adult and pediatric critical care . 📆Deadline: September 22, 2025 . 🔬Learn More Here: . 🖱️Submit here: @atscommunity
Tweet media one
0
2
4
@ATSBlueEditor
ATS Blue Journal
5 days
Addressing Sex as a Biological Variable in Preclinical Models of Lung Disease: An Official American Thoracic Society Research Statement.@atscommunity . 🔓 Open Access. 🔗
Tweet media one
0
0
2
@ATSBlueEditor
ATS Blue Journal
5 days
Don't miss out on this new episode of Breathe Easy!.
@atscommunity
American Thoracic Society (ATS)
5 days
Recent cuts and changes to the EPA have led experts to worry about how the increase in air pollution will negatively affect human health, especially for the thousands who suffer from respiratory conditions. Alison Lee, MD, discusses this and the other global impacts of these cuts
0
0
1
@ATSBlueEditor
ATS Blue Journal
5 days
The Blue Journal thanks Athénaïs Boucly, MD, PhD, for her contribution to the August issue. Clustering Patients with Pulmonary Hypertension Using the Plasma Proteome.@AthenaisBoucly .@imperialcollege .@APHP .
Tweet media one
0
0
1
@ATSBlueEditor
ATS Blue Journal
6 days
The Blue Journal thanks Xiaoqian Shan, MD, MS, for her contribution to the August issue. Deficient FANCL Predisposes Endothelial Damage: A New Therapeutic Target for Pulmonary Hypertension .
Tweet media one
0
0
1
@ATSBlueEditor
ATS Blue Journal
6 days
The Resilience of the Human Lungs: Evolution, Smoke, and Disease. Lung resilience evolved with fire exposure; studying protection in smokers may unlock new COPD therapies amid modern threats.@atscommunity . 🔓 Open Access. 🔗
0
5
13
@ATSBlueEditor
ATS Blue Journal
9 days
Telacebec, a Potent Agent in the Fight Against Tuberculosis: Findings from a Randomized, Phase 2 Clinical Trial and Beyond. Telacebec is a first-in-class agent with clinical activity against Mycobacterium TB, with dose-proportional pharmacokinetics. 🔗
Tweet media one
0
3
4
@ATSBlueEditor
ATS Blue Journal
9 days
A Telacebec-Shaped Puzzle Piece in the Treatment of Mycobacterial Diseases.@atscommunity . 🔓 Open Access. 🔗
0
0
0
@ATSBlueEditor
ATS Blue Journal
9 days
The Blue Journal thanks Shiyun Liu, MD, PhD, for her contribution to the August issue. Deficient FANCL Predisposes Endothelial Damage: A New Therapeutic Target for Pulmonary Hypertension .
Tweet media one
0
2
4
@ATSBlueEditor
ATS Blue Journal
9 days
RT @ATSBlueEditor: 📣Call for Papers! 📣 . Looking for articles highlighting the spectrum of discovery in thoracic malignancies . 📅….
0
1
0
@ATSBlueEditor
ATS Blue Journal
9 days
RT @ATSBlueEditor: 📣Call for Papers!📣. Looking for articles highlighting adult and pediatric critical care . 📆Deadline: September 22, 2025….
0
1
0
@ATSBlueEditor
ATS Blue Journal
10 days
“Social Apnea”: Obstructive Sleep Apnea is Exacerbated on Weekends.@atscommunity . 🔓 Open Access. 🔗
0
2
4
@ATSBlueEditor
ATS Blue Journal
10 days
The Blue Journal thanks Clove S. Taylor, BSc, for their contribution to the August issue. Biologic Mechanisms Underlying the Heterogeneous Response to Tight Glycemic Control among Differentially Inflamed Patients in the HALF-PINT Trial .@CloveTaylor .
Tweet media one
0
1
5